Skip to main content
Premium Trial:

Request an Annual Quote

MDx Health Raises $11.7M

By a GenomeWeb Staff Reporter

NEW YORK (GenomeWeb News) – MDx Health today announced it has raised €8.2 million ($11.7 million) in gross proceeds from a private placement of new shares with investors.

Net proceeds from the financing round, which exceeds the company's target of at least €6 million announced on Monday, will go toward accelerating the development of new products in line with its business restructuring to concentrate on the molecular diagnostics space. MDx Health also will use the funds to set up a CLIA laboratory and hire a sales and marketing firm in the US.

Pursuant to the private placement, the Liege, Belgium-based firm will issue approximately 5.4 million new ordinary shares at an offer price of €1.50 per share, it said.

"In combination with our existing cash position, these funds allow us to accelerate the executive of our new business strategy and establish a US presence in the short term," Jan Groen, CEO of MDx Health, said in a statement.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.